CRISPR/Cas9 technology was used to replace the genomic DNA sequence corresponding to amino acid 33–552 of the mouse Csf1 gene with the human CSF1 genomic sequence corresponding to amino acid 33–554 in the endogenous gene. The 5’ murine signal peptide (amino acid 1–32) and 3’ region of the mouse were retained.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by De Strooper
Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer's disease mouse model
Complement activation is implicated in driving brain inflammation, self-cell damage and progression of injury in Alzheimer's disease and other neurodegenerative diseases. Here, we investigate the impact of brain delivery of a complement-blocking antibody on neurodegeneration in an Alzheimer's mouse model. We engineered a brain-penetrant recombinant antibody targeting the pro-inflammatory membrane attack complex.
Regulation of human microglial gene expression and function via RNAase-H active antisense oligonucleotides in vivo in Alzheimer’s disease - Molecular Neurodegeneration
All ASOs were synthesized (Axolabs GmbH) as 20-mers with the 5 outer nucleosides on either end modified at the 2’ position of the ribose with methoxyethyl groups (2’MOE). The central 10 nucleosides were unmodified deoxynucleosides. All cytosines were methylated, and all internucleoside linkages were phosphorothioate. A total of 278 and 235 ASOs were synthesized to target APOE and TREM2 pre-mRNA, including exonic and intronic regions, respectively.
Understanding the Modulatory Role of E2012 on the γ-Secretase-Substrate Interaction
Cerebral deposition of amyloid plaques is a hallmark of Alzheimer’s disease (AD). The main components of these plaques are amyloid-β peptides (Aβ) that are synthesized when the amyloid precursor protein (APP) is cleaved by β-secretase to generate a transmembrane (TM) fragment of 99 residues (C99). C99 undergoes sequential cleavage by γ-secretase (GS) through two distinct pathways: Aβ48 → Aβ45 → Aβ42 → Aβ38 or Aβ49 → Aβ46 → Aβ43 → Aβ40 → Aβ37.
Apoptotic cell death in disease-Current understanding of the NCCD 2023
Cell Death and Differentiation, Apr 2023 This is a preview of a remote PDF: https://www.nature.com/articles/s41418-023-01153-w.pdf Vitale, Ilio, Pietrocola, Federico, Guilbaud, Emma, Aaronson, Stuart A., Abrams, John M., Adam, Dieter, Agostini, Massimiliano, Agostinis, Patrizia, Alnemri, Emad S., Altucci, Lucia, Amelio, Ivano, Andrews, David W., Aqeilan, Rami I., Arama, Eli, Baehrecke, Eric H., Balachandran, Siddharth, Bano, Daniele, Barlev, Nickolai A., Bartek, Jiri, Bazan, Nicolas G.,...
Defining Microglial States and Nomenclature: A Roadmap to 2030
44 Pages Posted: 23 Mar 2022 Publication Status: Under Review More... Abstract Microglial research has been constrained by a rolling series of dichotomies such as “resting versus activated” or “M1 versus M2”. This Manichean perspective of good or bad microglia is in sharp contrast with the wide repertoire of microglial functions, exerted from development to aging and diseases, brought to light in recent years.
Signalling dynamics in embryonic development
Skip Nav Destination Review Article| December 06 2021
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease - Nature Reviews Neurology
Abstract Alzheimer disease (AD) is the most common cause of dementia in older individuals (>65 years) and has a long presymptomatic phase. Preventive therapies for AD are not yet available, and potential disease-modifying therapies targeting amyloid-β plaques in symptomatic stages of AD have only just been approved in the United States.
Human stem cell-derived monocytes and microglia-like cells reveal impaired amyloid plaque clearance upon heterozygous or homozygous loss of TREM2
Claes, C; Van Den Daele, J; Boon, R; Schouteden, S; Colombo, A; Monasor, LS; Fiers, M; ... Verfaillie, CM; + view all Claes, C; Van Den Daele, J; Boon, R; Schouteden, S; Colombo, A; Monasor, LS; Fiers, M; Ordovás, L; Nami, F; Bohrmann, B; Tahirovic, S; De Strooper, B; Verfaillie, CM; - view fewer (2018) Human stem cell-derived monocytes and microglia-like cells reveal impaired amyloid plaque clearance upon heterozygous or homozygous loss of TREM2. Alzheimer's & Dementia 10.1016/j.jalz.2018.09.006.
BACE2 distribution in major brain cell types and identification of novel substrates
Voytyuk, I; Mueller, SA; Herber, J; Snellinx, A; Moechars, D; van Loo, G; Lichtenthaler, SF; Voytyuk, I; Mueller, SA; Herber, J; Snellinx, A; Moechars, D; van Loo, G; Lichtenthaler, SF; De Strooper, B; - view fewer (2018) BACE2 distribution in major brain cell types and identification of novel substrates. Life Science Alliance , 1 (1) , Article e201800026. 10.26508/lsa.201800026.
Self-Maintaining Gut Macrophages Are Essential for Intestinal Homeostasis
De Schepper, S; Verheijden, S; Aguilera-Lizarraga, J; Viola, MF; Boesmans, W; Stakenborg, N; Voytyuk, I; ...
Deregulation of neuronal miRNAs induced by amyloid-β or TAU pathology
Sierksma, A; Lu, A; Salta, E; Vanden Eynden, E; Callaerts-Vegh, Z; D'Hooge, R; Blum, D; ... De Strooper, B; + view all Sierksma, A; Lu, A; Salta, E; Vanden Eynden, E; Callaerts-Vegh, Z; D'Hooge, R; Blum, D; Buée, L; Fiers, M; De Strooper, B; - view fewer (2018) Deregulation of neuronal miRNAs induced by amyloid-β or TAU pathology. Molecular Neurodegeneration , 13 (54) 10.1186/s13024-018-0285-1.
Increased Insoluble Amyloid-β Induces Negligible Cognitive Deficits in Old AppNL/NL Knock-In Mice
Salas, IH; Callaerts-Vegh, Z; D'Hooge, R; Saido, TC; Dotti, CG; De Strooper, B; (2018) Increased Insoluble Amyloid-β Induces Negligible Cognitive Deficits in Old AppNL/NL Knock-In Mice. Journal of Alzheimer's Disease , 66 (2) pp. 801-809. 10.3233/JAD-180410. Commonly used Alzheimer's disease mouse models are based on the ectopic overexpression of the human amyloid precursor protein (APP) gene, together with a mutant presenilin gene.
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Abstract Alzheimer’s disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with De
Contact De, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack